This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Neuromyotonia (Isaacs syndrome)Neuromyotonia (Isaacs Syndrome / Acquired Neuromyotonia)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: G71.1 | Special Copayment Reduction: V012 | Registration validity period: 5 years
B. SynonymsNeuromyotonia [Isaacs], Isaacs syndrome, acquired neuromyotonia, continuous muscle fiber activity syndrome, Morvan syndrome (partial overlap), Isaacs-Mertens syndrome
C. Adult onsetHigh likelihood of first onset in adulthood — appears mainly in adults aged 15–60, with higher frequency in middle-aged men.
1. HistoryGo to section
2. CausesGo to section
3. GeneticsGo to section
4. General epidemiologyGo to section
5. PathophysiologyGo to section
6. SymptomsGo to section
7. SignsGo to section
8. ScreeningGo to section
9. DiagnosisGo to section
10. TreatmentGo to section
11. PrognosisGo to section
12. PreventionGo to section
13. ReferencesGo to section

1. History

Neuromyotonia (NMT) was medically established in 1961 when the American neurologist Hyam Isaacs first systematically described a peculiar clinical syndrome with continuous muscle activity, muscle twitching, stiffness, and sweating as its main symptoms, under the name 'Syndrome of continuous muscle fibre activity'. It subsequently came to be called 'Isaacs syndrome' after him. Mertens and Zschocke described a similar syndrome independently of Isaacs, so it is also called 'Isaacs-Mertens syndrome'. That the disease is due to spontaneous muscle activity originating in peripheral nerves was gradually established through EMG studies in the 1960s–1980s. Decisive evidence for an autoimmune pathogenesis was provided in 1995 when Hart et al. first detected autoantibodies against the voltage-gated potassium channel (VGKC) complex in the serum of patients with Isaacs syndrome. Since the 2010s, understanding of the pathogenesis has deepened as CASPR2 (Contactin-associated protein-like 2) antibodies and LGI1 (Leucine-rich glioma-inactivated 1) antibodies were identified as the main target antigens, and a paraneoplastic association with malignant tumors (thymoma, lung cancer, etc.) has also been revealed in some patients.

2. Causes

Neuromyotonia is an autoimmune disease caused mainly by autoantibodies against the voltage-gated potassium channel (VGKC) complex of peripheral motor nerves (particularly distal peripheral nerves and sites proximal to the neuromuscular junction).

3. Genetics

Most neuromyotonia is an acquired autoimmune disease, not a genetic disease. However, a rare hereditary form due to KCNA1 gene (12p13) variants has been reported. There are also studies suggesting that HLA (human leukocyte antigen) polymorphisms may be involved in susceptibility to autoimmune neuromyotonia, but no clinically established genetic marker exists yet. An association with HLA-DRB1*11:01 has been reported in CASPR2-Ab-positive patients. Therefore, the role of genetic counseling in neuromyotonia is limited, and the diagnostic approach centers on autoantibody testing and screening for malignant tumors.

4. General epidemiology

Neuromyotonia is a rare disease, and its exact prevalence is difficult to determine. It is estimated at about 1–2 per million population worldwide, but the actual prevalence may be higher due to underdiagnosis. It occurs mainly in adults aged 15–60 but can occur at any age. It tends to occur slightly more often in men than in women. Some reports indicate that malignant tumors (especially thymoma) accompany about 20–40% of acquired neuromyotonia. Occurrence in children is rare, and CASPR2-Ab and LGI1-Ab are also detected in pediatric neuromyotonia. Tumor-associated neuromyotonia is more common in men and in older age.

5. Pathophysiology

The core pathogenesis of neuromyotonia is inhibition of channel function by autoantibodies targeting the voltage-gated potassium channel (VGKC) complex of peripheral motor nerves.

CASPR2 and LGI1 are synaptic adhesion proteins associated with the VGKC complex (in particular, a protein complex that includes the Kv1.1 and Kv1.2 channels). When autoantibodies bind to this complex, expression of voltage-gated potassium channels decreases or their function declines. Because potassium channels are responsible for rapid repolarization after an action potential, impairment of this function results in hyperexcitability of motor nerve terminals.

As a result, spontaneous, repetitive action potentials occur continuously in peripheral motor nerves even without a single voluntary nerve stimulus. These abnormal nerve impulses are transmitted to muscle through the neuromuscular junction, producing continuous muscle contraction, fasciculation, muscle undulation, stiffness, and pseudomyotonia.

Autonomic nervous system involvement: similar hyperexcitability occurs in autonomic nerve fibers, accompanied by autonomic symptoms such as hyperhidrosis and abnormal heart rate variability. Central nervous system involvement: CASPR2-Ab can also bind target proteins in the brain and cause central nervous system symptoms (insomnia, hallucinations, cognitive impairment) such as in Morvan syndrome.

6. Symptoms

Muscle-related symptoms

Autonomic symptoms

Central nervous system symptoms (Morvan syndrome form)

Other

7. Signs

Physical examination

EMG findings (key diagnostic evidence)

Laboratory findings

8. Screening

9. Diagnosis

Diagnosis is made by a combination of clinical symptoms (continuous muscle activity, hyperhidrosis), characteristic EMG findings (neuromyotonic discharges), and serum autoantibody testing.

Diagnostic criteria (clinical consensus)

Antibody testing

Differential diagnosis

10. Treatment

Treatment proceeds in two directions: (1) membrane-stabilizing drugs for symptom control, and (2) immunotherapy to block the autoimmune mechanism.

Symptom control (membrane-stabilizing drugs)

Immunotherapy

Tumor treatment

11. Prognosis

The prognosis of neuromyotonia varies with the cause, type of autoantibody, and treatment response. When an autoimmune mechanism is confirmed, the response to immunotherapy is good, and symptoms improve markedly or remit in a considerable proportion of appropriately treated patients. The prognosis is good when thymoma is detected early and resected in CASPR2-Ab-positive patients. However, relapse is common when immunotherapy is stopped, so long-term maintenance treatment is often needed. Morvan syndrome (with central nervous system involvement) may have a worse prognosis than neuromyotonia alone. The treatment response is relatively poor in antibody-negative patients or when there is a paraneoplastic cause. Life-threatening complications include severe autonomic dysfunction (cardiac arrhythmia, severe orthostatic hypotension), but these are rare.

12. Prevention

13. References

  1. Isaacs H. A syndrome of continuous muscle-fibre activity. J Neurol Neurosurg Psychiatry. 1961;24:319–325. PMID: 13884290
  2. Hart IK, Waters C, Vincent A, et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol. 1997;41(2):238–246. PMID: 9029073
  3. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734–2748. PMID: 20663977
  4. Vernino S, Lennon VA. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve. 2002;26(5):702–707. PMID: 12402293
  5. Maddison P. Neuromyotonia. Clin Neurophysiol. 2006;117(10):2118–2127. PMID: 16769245
  6. Hacohen Y, Brownlee W, Wenmaekers M, et al. Acquired neuromyotonia in children with CASPR2 and LGI1 antibodies. Neurology. 2019;92(12):e1293–e1300. PMID: 30724344
  7. Shillito P, Molenaar PC, Vincent A, et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol. 1995;38(5):714–722. PMID: 7486861
  8. Li X, Liu Y, Zheng X, et al. Rituximab was effective in relieving symptoms of Isaacs syndrome: a case report. Front Immunol. 2022;13:1016625. PMC: 9642979
  9. Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain. 1993;116(Pt 2):453–469. PMID: 8461968
  10. Boërio D, Lefaucheur JP, Bassez G, Créange A. Central and peripheral components of exercise-related fatigability in myotonic dystrophy type 1. Neurophysiol Clin. 2012;42(3):129–138. PMID: 22507353